This document summarizes the experiences of surgeons at a German hospital in using mechanical circulatory support devices for pediatric patients between 1987-2004. It provides details on:
1) 29 pediatric patients received ventricular assist devices (VADs) including LVADs, BVADs, and ECMO for conditions like cardiomyopathy and congenital heart disease.
2) The most common devices used were Thoratec VADs, Medos-HIA VADs, and ECMO. Support times ranged from 11 to 231 days.
3) Major complications included bleeding in 24% of cases, thrombosis in 21%, and infection in 28%. 16 patients died during support while 10 received heart transplants.
2017 Barcelona. Acute Cardiac Unloading and Recovery Working Group Meeting.
The Impella ventricular assist device support experience at Texas Children's Hospital.
The field of perfusion is becoming increasingly demanding both clinically and didactically. As the patient population continues to present with a variety of complex health issues, there is a greater need than ever for the Pefusionist to develop new techniques for patient care while on Cardiopulmonary Support. Ascending Aortic Arch dissections (AAAD), with its current mortality rates of 10%-15% with significant neurological complications associated, still remains a difficult case for Perfusionist’s to manage effectively. The most widely used technique during this type of repair surgery, is hypothermic circulatory arrest (HCA). Although this remains a premier technique, there continues to be a high reported incidence of neurological deficit post HCA. In order to address and limit this issue, the advent of selective cerebral perfusion is slowly gaining acceptance. This new technique has been shown to not only decrease the time of exposure of blood to a foreign surface, but limit the patient duration on full cardiopulmonary support. The most notable aspect of this technique; is it allows the surgeon to begin repairs immediately, since the process cools the brain only, while keeping the rest of body at moderate-mild hypothermic levels.
ECMO CPR
ECMO in Cardiac arrest has increased exponentially in the past 10 years, on the back of, up until very recently, non-randomised, predominantly retrospective studies.
What is the efficacy?
Appropriate patient selection?
Cost effectiveness and model of delivery of ECPR?
Finally is ECMO really the intervention or just optimising the chain of survival?
2017 Barcelona. Acute Cardiac Unloading and Recovery Working Group Meeting.
The Impella ventricular assist device support experience at Texas Children's Hospital.
The field of perfusion is becoming increasingly demanding both clinically and didactically. As the patient population continues to present with a variety of complex health issues, there is a greater need than ever for the Pefusionist to develop new techniques for patient care while on Cardiopulmonary Support. Ascending Aortic Arch dissections (AAAD), with its current mortality rates of 10%-15% with significant neurological complications associated, still remains a difficult case for Perfusionist’s to manage effectively. The most widely used technique during this type of repair surgery, is hypothermic circulatory arrest (HCA). Although this remains a premier technique, there continues to be a high reported incidence of neurological deficit post HCA. In order to address and limit this issue, the advent of selective cerebral perfusion is slowly gaining acceptance. This new technique has been shown to not only decrease the time of exposure of blood to a foreign surface, but limit the patient duration on full cardiopulmonary support. The most notable aspect of this technique; is it allows the surgeon to begin repairs immediately, since the process cools the brain only, while keeping the rest of body at moderate-mild hypothermic levels.
ECMO CPR
ECMO in Cardiac arrest has increased exponentially in the past 10 years, on the back of, up until very recently, non-randomised, predominantly retrospective studies.
What is the efficacy?
Appropriate patient selection?
Cost effectiveness and model of delivery of ECPR?
Finally is ECMO really the intervention or just optimising the chain of survival?
Outcome After Procedures for Retained Blood Syndrome in Coronary SurgeryPaul Molloy
OBJECTIVES:
Incomplete drainage of blood from around the heart and lungs can lead to retained blood syndrome (RBS) after cardiac sur-
gery. The aim of this study was to assess the incidence of and the outcome after procedures for RBS in patients undergoing isolated coronary artery bypass grafting (CABG)-
Hergen Buscher is an Intensivist from St Vincent's hospital in Sydney. He has extensive experience with ECMO, in both veno-venous and veno-arterial contexts. Listen to this talk he gave on the most recent developments in ECMO and where things are heading.
This talk was given live in September 2014 for an Intensive Care Network (ICN) NSW meeting.
Go to www.intensivecarenetwork.com for more.
Hepatic Vein Blood Increases Lung Microvascular Angiogenesis and Endothelial ...KarthikeyanThirugnan3
To improve our understanding of pulmonary arteriovenous malformations in univentricular congenital heart disease, our objective was to identify the effects of hepatic vein and superior vena cava constituents on lung microvascular endothelial cells independent of blood flow. Paired blood samples were collected from the hepatic vein and superior vena cava in children 010 years old undergoing cardiac catheterization. Isolated serum was subsequently used for in vitro endothelial cell assays.
Angiogenic activity was assessed using tube formation and scratch migration. Endothelial cell survival was assessed using proliferation (BrdU incorporation, cell cycle analysis) and apoptosis (caspase 3/7 activity, Annexin-V labeling). Data were analyzed using Wilcoxon signed-rank test and repeated measures analysis. Upon incubating lung microvascular endothelial cells with 10% patient serum, hepatic vein
serum increases angiogenic activity (tube formation, P = 0.04, n = 24; migration, P< 0.001, n = 18), increases proliferation (BrdU, P < 0.001, n=32 S-phase, P= 0.04, n = 13), and decreases apoptosis (caspase 3/7, P < 0.001, n = 32; Annexin-V, P = 0.04, n = 12) compared to superior vena cava serum. Hepatic vein serum regulates lung microvascular endothelial cells by increasing angiogenesis and survival in vitro. Loss of hepatic vein serum signaling in the lung microvasculature may promote maladaptive lung microvascular remodeling and pulmonary arteriovenous malformations.
Acute type A dissection, is on of the highest mortality cases in cardiovascular surgery. It doubled it incident with concomitant complication such as malperfusion or pericardial tamponade. In this presentation, the patient have both coronary malperfusion and pericardial tamponade
Does Serum Lactate and Central Venous Saturation Predict Perioperative Outcom...crimsonpublishersOJCHD
Off-pump coronary artery bypass grafting (OP-CABG) surgery without the use of cardiopulmonary bypass (CPB) has come into practice for surgical treatment of Coronary artery disease (CAD) to reduce the post-operative systemic inflammatory response and post-operative morbidity. However, manipulation of the beating heart during OP-CABG surgery brings significant fluctuations in the patients haemodynamics leading to occult hypo-perfusion and 'Global tissue hypoxia' (GTH) -a decrease in oxygen utilization associated with anaerobic metabolism.
Myocardial viability testing all STICHed up, or about to be REVIVEDNicolas Ugarte
Patients with ischaemic left ventricular dysfunction frequently undergo myocardial viability testing. The historical model presumes that
those who have extensive areas of dysfunctional-yet-viable myocardium derive particular benefit from revascularization, whilst those without extensive viability do not. These suppositions rely on the theory of hibernation and are based on data of low quality: taking a dogmatic
approach may therefore lead to patients being refused appropriate, prognostically important treatment. Recent data from a sub-study of
the randomized STICH trial challenges these historical concepts, as the volume of viable myocardium failed to predict the effectiveness of
coronary artery bypass grafting. Should the Heart Team now abandon viability testing, or are new paradigms needed in the way we interpret viability? This state-of-the-art review critically examines the evidence base for viability testing, focusing in particular on the presumed
interactions between viability, functional recovery, revascularization and prognosis which underly the traditional model. We consider
whether viability should relate solely to dysfunctional myocardium or be considered more broadly and explore wider uses of viability testingoutside of revascularization decision-making. Finally, we look forward to ongoing and future randomized trials, which will shape evidence-based clinical practice in the futur
Short term MCS as the parachute... non RCTs in support... but try to launch out of the plane without it ;-)
Slides from the first hospital meeting On the use of MCS systems.
Outcome After Procedures for Retained Blood Syndrome in Coronary SurgeryPaul Molloy
OBJECTIVES:
Incomplete drainage of blood from around the heart and lungs can lead to retained blood syndrome (RBS) after cardiac sur-
gery. The aim of this study was to assess the incidence of and the outcome after procedures for RBS in patients undergoing isolated coronary artery bypass grafting (CABG)-
Hergen Buscher is an Intensivist from St Vincent's hospital in Sydney. He has extensive experience with ECMO, in both veno-venous and veno-arterial contexts. Listen to this talk he gave on the most recent developments in ECMO and where things are heading.
This talk was given live in September 2014 for an Intensive Care Network (ICN) NSW meeting.
Go to www.intensivecarenetwork.com for more.
Hepatic Vein Blood Increases Lung Microvascular Angiogenesis and Endothelial ...KarthikeyanThirugnan3
To improve our understanding of pulmonary arteriovenous malformations in univentricular congenital heart disease, our objective was to identify the effects of hepatic vein and superior vena cava constituents on lung microvascular endothelial cells independent of blood flow. Paired blood samples were collected from the hepatic vein and superior vena cava in children 010 years old undergoing cardiac catheterization. Isolated serum was subsequently used for in vitro endothelial cell assays.
Angiogenic activity was assessed using tube formation and scratch migration. Endothelial cell survival was assessed using proliferation (BrdU incorporation, cell cycle analysis) and apoptosis (caspase 3/7 activity, Annexin-V labeling). Data were analyzed using Wilcoxon signed-rank test and repeated measures analysis. Upon incubating lung microvascular endothelial cells with 10% patient serum, hepatic vein
serum increases angiogenic activity (tube formation, P = 0.04, n = 24; migration, P< 0.001, n = 18), increases proliferation (BrdU, P < 0.001, n=32 S-phase, P= 0.04, n = 13), and decreases apoptosis (caspase 3/7, P < 0.001, n = 32; Annexin-V, P = 0.04, n = 12) compared to superior vena cava serum. Hepatic vein serum regulates lung microvascular endothelial cells by increasing angiogenesis and survival in vitro. Loss of hepatic vein serum signaling in the lung microvasculature may promote maladaptive lung microvascular remodeling and pulmonary arteriovenous malformations.
Acute type A dissection, is on of the highest mortality cases in cardiovascular surgery. It doubled it incident with concomitant complication such as malperfusion or pericardial tamponade. In this presentation, the patient have both coronary malperfusion and pericardial tamponade
Does Serum Lactate and Central Venous Saturation Predict Perioperative Outcom...crimsonpublishersOJCHD
Off-pump coronary artery bypass grafting (OP-CABG) surgery without the use of cardiopulmonary bypass (CPB) has come into practice for surgical treatment of Coronary artery disease (CAD) to reduce the post-operative systemic inflammatory response and post-operative morbidity. However, manipulation of the beating heart during OP-CABG surgery brings significant fluctuations in the patients haemodynamics leading to occult hypo-perfusion and 'Global tissue hypoxia' (GTH) -a decrease in oxygen utilization associated with anaerobic metabolism.
Myocardial viability testing all STICHed up, or about to be REVIVEDNicolas Ugarte
Patients with ischaemic left ventricular dysfunction frequently undergo myocardial viability testing. The historical model presumes that
those who have extensive areas of dysfunctional-yet-viable myocardium derive particular benefit from revascularization, whilst those without extensive viability do not. These suppositions rely on the theory of hibernation and are based on data of low quality: taking a dogmatic
approach may therefore lead to patients being refused appropriate, prognostically important treatment. Recent data from a sub-study of
the randomized STICH trial challenges these historical concepts, as the volume of viable myocardium failed to predict the effectiveness of
coronary artery bypass grafting. Should the Heart Team now abandon viability testing, or are new paradigms needed in the way we interpret viability? This state-of-the-art review critically examines the evidence base for viability testing, focusing in particular on the presumed
interactions between viability, functional recovery, revascularization and prognosis which underly the traditional model. We consider
whether viability should relate solely to dysfunctional myocardium or be considered more broadly and explore wider uses of viability testingoutside of revascularization decision-making. Finally, we look forward to ongoing and future randomized trials, which will shape evidence-based clinical practice in the futur
Short term MCS as the parachute... non RCTs in support... but try to launch out of the plane without it ;-)
Slides from the first hospital meeting On the use of MCS systems.
A Case Report of Hypothermia Rescued by Veno-Arterial Extracorporeal Membrane...semualkaira
Severe hypothermia is a life-threatening condition that often causes hemodynamic instability or cardiac arrest
and carries a high risk of mortality. The use of VA-ECMO in this
indication has greatly improved the prognosis of patients.
A Case Report of Hypothermia Rescued by Veno-Arterial Extracorporeal Membrane...semualkaira
Severe hypothermia is a life-threatening condition that often causes hemodynamic instability or cardiac arrest
and carries a high risk of mortality. The use of VA-ECMO in this
indication has greatly improved the prognosis of patients.
A Case Report of Hypothermia Rescued by Veno-Arterial Extracorporeal Membrane...semualkaira
Severe hypothermia is a life-threatening condition that often causes hemodynamic instability or cardiac arrest and carries a high risk of mortality. The use of VA-ECMO in this indication has greatly improved the prognosis of patients
A Case Report of Hypothermia Rescued by Veno-Arterial Extracorporeal Membrane...semualkaira
Severe hypothermia is a life-threatening condition that often causes hemodynamic instability or cardiac arrest and carries a high risk of mortality. The use of VA-ECMO in this indication has greatly improved the prognosis of patients
A Case Report of Hypothermia Rescued by Veno-Arterial Extracorporeal Membrane...semualkaira
Severe hypothermia is a life-threatening condition that often causes hemodynamic instability or cardiac arrest
and carries a high risk of mortality. The use of VA-ECMO in this
indication has greatly improved the prognosis of patients
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Suporte circulatório ventricular mecânico em pediatria
1. 307Ann Thorac Cardiovasc Surg Vol. 11, No. 5 (2005)
Original
Article
Introduction
The incidence of severe heart failure due to acute myo-
carditis, idiopathic cardiomyopathy and congenital heart
disease (CHD) is estimated ca. 200 patients/1 million in
Germany. Generally there are not enough donor hearts
for children in any country, therefore we sometimes use
the mechanical circulation support system for these chil-
dren. In this respect the mechanical circulatory support
system has been receiving increasing attention.
The aims for application of mechanical circulatory
support are as follows:
1) To maintain systemic circulation
2) To avoid multiple organ failure
3) To bridge for heart transplantation
Recently, various mechanical circulatory support sys-
tems, centrifugal pumps or pneumatic assist devices, are
being used worldwide, nevertheless the size of device lim-
its implantation in pediatric cases. Accordingly we re-
port our experiences with assist devices applied for pedi-
atric patients.
MechanicalVentricular Circulatory Support in
Children; Bad Oeynhausen Experience
Kazutomo Minami, MD, PhD,1
Edzard von Knyphausen, MD,2
Ryusuke Suzuki, MD,1
Ute Blanz, MD,1
Latif Arusoglu, MD,1
Michael Morshuis, MD,1
Aly El-Banayosy, MD,1
and Reiner Körfer, MD, PhD1
From Departments of 1
Thoracic and Cardiovascular Surgery, and
2
Department of Pediatric Cardiology, Heart and Diabetes Center
North Rhine-Westphalia, Ruhr University of Bochum, Bad
Oeynhausen, Germany
Received February 15, 2005; accepted for publication March 16,
2005.
Address reprint requests to Kazutomo Minami, MD, PhD: Depart-
ment of Thoracic and Cardiovascular Surgery, Heart and Diabetes
Center North Rhine-Westphalia, Ruhr University of Bochum,
Georgstrasse 11, 32545 Bad Oeynhausen, Germany.
Read at The 40th Annual Meeting of Japanese Society of Pediatric
Cardiology and Cardiac Surgery, June 30-July 2, 2004, Tokyo, Japan.
Introduction: Recently various mechanical circulatory support systems are being used all over
the world, nevertheless the size of the devices limits the implantation in pediatric cases.Accord-
ingly we report our experiences with assist devices applied for pediatric patients.
Patients and Methods: Twenty-nine children underwent mechanical circulatory support im-
plantation operation. The diagnoses of preoperation were dilated cardiomyopathy in 16, con-
genital heart disease in 12 and allograft dysfunction in 1.
Results: From November 1987 to January 2004 we implanted 7 LVAD, 11 BVAD and 11 ECMO
in pediatric patients. The 29 patients were supported from 11 to 231 days (mean 32.3 days).
Three children were supported by Thoratec LVAD. Biventricular Thoratec®
VAD was used in 3
children. Three children were supported by Medos-HIA system LVAD, and 8 children by
biventricular VAD using the Medos-HIA system. One child was supported by Novacor®
LVAD.
Fourteen children were supported by ECMO. We succeeded in heart transplantation in 10 cases,
but lost 16 children during the support. Bleeding occurred in 7 cases, thrombosis occurred in 6
cases, infection occurred in 8 cases, pneumothorax occurred in 3 cases and neurological deficit
occurred in 2 cases.
Conclusion: The development of assist device for children which has long durability and small
in size as a future subject is desired. Further clinical and experimental research and application of
those assist devices for children are in progress. (AnnThorac Cardiovasc Surg 2005; 11: 307–12)
Key words: mechanical circulatory support, heart transplantation, pediatric patient
2. 308
Minami et al.
Ann Thorac Cardiovasc Surg Vol. 11, No. 5 (2005)
Patients and Methods
790 cases underwent mechanical cardiac support opera-
tion at our hospital from November 1987 to January 2004.
Twenty nine of them were pediatric cases (3.7%). In pe-
diatric cases for mechanical circulatory support we have
implanted extracorporeal membrane oxygenation
(ECMO) by centrifugal pump, Thoratec ventricular as-
sist device (Thoratec®
VAD; Thoratec Corporation,
Pleasanton, CA, USA), Novacor®
ventricular assist
device (Novacor LVAS; Baxter Healthcare Corp., Oak-
land, CA, USA) or Medos-HIA VAD system (Medos-
Helmholtz Institute, Aachen, Germany). We used ECMO
or left ventricular assist device (LVAD) or biventricular
assist device (BVAD) for postcardiotomy heart failure. If
the purpose was bridging for heart transplantation, we
used a single ventricular assist device or BVAD.
Our indications for mechanical circulatory support are
1) low output syndrome under optimal inotropic support,
2) agitation, disturbed consciousness, 3) cardiac index <2
l/min/kg, 4) urine output <1 ml/min/kg, 5) central venous
pressure >15 mmHg.
Patient population
Twenty nine children underwent mechanical circulatory
support implantation operation. Table 1 shows clinical
characteristics of patients. The preoperative diagnosis
were dilated cardiomyopathy (DCM) in 16, CHD in 12
(transposition of great arteries (TGA):1, tetralogy of Fallot
(TOF):1, double-inlet right ventricle (DILV) + TGA:1,
ventricular septal defect (VSD):1, pulmonary artery atre-
sia (PAA):1) and allograft failure in 1. Mean age was 5.2
years old (1.6-17.7 years old). Male and female ratio was
17/12. Patients weight ranged from 3.0 to 78.0 kg (mean
8.7 kg).
Type of devices
1) ECMO system
Our ECMO system has a Bio-Medicus centrifugal pump
(Bio-Medicus Co, Eden Prairie, MN, USA) and oxygen-
ation system. The outflow cannulation site was the
ascending aorta and venous cannulation was the right
atrium in all cases.
2) Thoratec
The pump is placed in the paracorporeal position and the
system consists of prosthetic ventricles with a 65 ml stroke
volume and appropriate cannulas for atrial or ventricular
inflow and arterial outflow connections. Ventricular de-
vices are controlled either with a hospital-based pneu-
matic drive console or with a portable drive unit.1)
3) Novacor LVAS
The system is partially implantable. The device is driven
by electrical solenoid energy and has porcine valves in
outflow and inflow. Ventricular device is controlled
either with a hospital-based drive console or with a
portable drive unit in the same way as the Thoratec
controller.
4) Medos-HIA VAD system
The system is driven pneumatically, available in three
different ventricular sizes of 10, 25, and 60 ml. For right
ventricular, we are able to implant the 10% smaller sizes
of 9, 22.5, and 54 ml. The system has been developed by
Reul and coworkers at the Helmholtz Institute in Aachen,
Germany. The system is not heparin coated and has poly-
urethane trileaflet valves.
Thoratec®
, Novacor®
or Medos-HIA systems were
placed using a median sternotomy with a cardiopulmo-
nary bypass in all cases. In the left ventricle assist case,
the outflow cannulation site was the ascending aorta and
inflow cannulation was the apex of the left ventricle in
all cases. Otherwise in right ventricle assist cases the out-
flow cannulation site was the pulmonary artery and the
inflow cannulation was the right atrium.
Results
Device support
From November 1987 to January 2004 we implantedVAD
for 29 pediatric patients; LVADs in 7 cases, BVADs in 11
cases and ECMOs in 11 cases. The mean duration of the
supporting time was 32.3 days (range from 11 days to
231 days). The mean duration of the patients in whom
the ECMO system was implanted was 3.1 days. With the
Medos-HIA system the mean duration of the patients was
Table 1. Clinical charateristics of patients
DCM, dilated cardiomyopathy; CHD, congenital heart dis-
ease; TGA, transposition of great arteries; TOF, tetralogy of
Fallot; DILV, double inlet left ventricle; VSD, ventricular
septal defect; PAA, pulmonary artery atresia
Age (year)
Male/female
Body weight (kg)
Diagnosis
DCM
CHD
(TGA;8, TOF;1, DILV+TGA;1, VSD;1, PAA;1)
Allograft dysfunction
1.6-17.7 (m=5.2)
17/12
3.0-78.0 (m=8.7)
Cases
16
12
1
3. 309
Mechanical Ventricular Circulatory Support in Children
Ann Thorac Cardiovasc Surg Vol. 11, No. 5 (2005)
23.8 days. The patients with an implanted Thoratec sys-
tem had a mean duration of 72.8 days.
Three children were supported by Thoratec LVAD.
Three children were supported by biventricular Thoratec®
VAD. In Thoratec®
VAD cases the mean body weight of
patients was 42.3 kg. Three children were supported by
the Medos-HIA system LVAD. Eight children were sup-
ported by the Medos-HIA system BVAD. Three of them
were exchanged to the Medos-HIA system from ECMO.
On 3 children we used a 10 ml pump for left ventricle.
The mean body weight was 4.1 kg. On another 8 children
we used a 25 ml pump for left ventricle. The mean body
weight was 16.4 kg. One child was supported by Novacor®
LVAD (body weight was 78.0 kg). Fourteen children were
supported by ECMO (Table 2). The mean age of those
with ECMO supported was 4.2 years old, whereas the
mean age of patients with VAD was 12.7 years old.
Complications
Table 3 presents the complications in those children. The
major complications were bleeding, thrombosis and in-
fection. Bleeding occurred in 7 cases (24.1%), thrombo-
sis occurred in 6 cases (20.7%), infection (local or sys-
tem) occurred in 8 cases (28.3%), pneumothorax occurred
in 3 cases (10.3%) and neurological deficit occurred in 2
cases (6.9%). A bleeding complication was defined as
blood loss of more than 1,500 ml/m2
in 24 hours. A neu-
rologic complication was defined as neurologic deficits
proven and differentiated by computed tomographic scan.
Infection definition included several parts: a pocket in-
fection was defined as being associated with local signs
of infection with purulent secretions and with positive
bacterial cultures. The presence of a septic complication
was indicated by a body temperature above 38.5°C, white
blood cell count more than 12,000/mm3
, high output
states, low systemic vascular resistance, and positive blood
cultures.
Outcome
Figure 1 shows our latest results. In the LVAD implanted
group, 5 children received heart transplantation, 1 child
died and 1 case was weaned from LVAD and is still alive
now. In the BVAD implanted group, 3 received heart trans-
plantation and another 8 died. In the ECMO implanted
group, 2 of them received heart transplantation, 7 died
and 2 were weaned off from ECMO and are still alive
now.
We succeeded in heart transplantation in 10 cases
(34.5%), but lost 16 children during the support. Total
survival rate was 44.8%.
Discussion
In recent years the number of pediatric patients who re-
quire heart transplantation has increased. About a quarter
of pediatric patients die while awaiting heart transplanta-
tion. During this time, many patients need extensive cir-
culatory support, for example high dosed inotropic sup-
port or circulatory assist device. In end-staged patients to
avoid multiple organ failure; renal failure or liver dys-
function, some kind of mechanical circulatory support is
necessary.2,3)
There are a lot of reports that describe successful use
of ECMO as a bridge to heart transplantation in pediatric
patients.4,5)
ECMO is the most familiar and readily available, but
is not suitable for long term use in contrast to other assist
devices. The ECMO sustains the circulation for several
Table 2. Mechanical ventricular circulatory support
LVAD
BVAD
ECMO
Assist devices
7
11
11 (+3)
Cases
Support time (days)
Heart transplantation
Death during support
Results
11-231 (m=32.3)
10 (34.5%)
15 (51.7%)
Thoratec
LVAD
BVAD
Medos-HIA
LVAD
BVAD
Novacor LVAD
ECMO
Systems
3
3
3
8 (3 after ECMO)
1
14
Cases
LVAD, left ventricular assist device; BVAD, biventricular
assist device; ECMO, extracorporeal membrane oxygenation
Table 3. Mechanical ventricular circulatory support
Bleeding
Thrombembolism
Infection (local or system)
Pneumothorax
Neurological deficit
Complications during MCS
7 (24.1)
6 (20.7)
8 (28.3)
3 (10.3)
2 (6.9)
Cases (%)
MCS, mechanical circulatory support
4. 310
Minami et al.
Ann Thorac Cardiovasc Surg Vol. 11, No. 5 (2005)
days, maximal a few weeks.6-8)
The ECMO system re-
quires constant monitoring and adjustment by a
perfusionist or a physician. Furthermore, we have to be
concerned about the risk of bleeding or infectious com-
plications. Patients usually cannot be extubated and mo-
bilized.9)
Furthermore, vascular access has been a prob-
lem in ECMO cannulation. Even the question of whether
the use of the carotid artery for outflow induces neuro-
logical complications is now controversial. The ECMO
system is very easy to implant, but we found two prob-
lems, one of them is that the durability is very short, the
other is that the flow of device is not a pulsatile flow.
Levi et al. described that patients with pulsatile VAD had
stable hemodynamics and a high quality of life.5)
The use
of ECMO after cardiac surgery has shown to be success-
ful especially in small children with myocardial failure.
If there is no pulmonary dysfunction, ECMO is not al-
ways the optimal method for prolonged circulatory sup-
port. The advantages of ECMO systems are easier can-
nulation and oxygenated support in pulmonary dysfunc-
tion.10)
Some authors reported the usefulness of an intraaortic
balloon pump.11,12)
Nevertheless, the effectiveness of
intraaortic balloon pumps is still limited in small chil-
dren and infants by increased aortic elasticity, rapid heart
rate with small stroke volumes, and the difficulty of in-
sertion into a small artery. Furthermore the intraaortic bal-
loon pump has limited effectiveness in patients who suf-
fer from right heart dysfunction.11)
The VAD by centrifugal pump is easy to use and avail-
able world widely. Several recent reports describe the abil-
ity of the VAD by centrifugal pump.13-15)
If necessary, two
centrifugal pumps are used for biventricular assistance.
Certainly the cost is relatively inexpensive. However, as
with the ECMO system too, patients cannot be mobilized
and must stay in the intensive care unit.16)
Duncan and
coworkers reported the availability of the ECMO and the
VAD by the centrifugal pump. In that report they treated
106 children (67 cases ECMO, 29 cases VAD). In the
ECMO group 45 cases were successfully weaned off and
27 cases survived. In the VAD group 19 cases were suc-
cessfully weaned off and 12 cases survived.13)
However,
the median duration of support was relative short; 4.8 days
in the ECMO group and 1.8 days in the VAD group.
Since 1990 new assist devices for pediatric patients
are available in Germany. One of them is the Medos-HIA
VAD system, another one is the Berlin Heart VAD. Both
those new assist devices are pulsatile VAD, in the
paracorporeal position. Children on prolonged pulsatile
VAD support may take part in everyday activities and have
closer contact with their families when awake and extu-
bated.16)
There were less hemorrhagic and thromboembolic
complications than with the ECMO system.17-19)
We had
11 pediatric cases with these devices. Three of them were
implanted as LVAD, the other as BVAD.
Another Berlin Heart VAD (Berlin Heart AG, Berlin,
Germany) is driven pneumatically, too, and the ventricu-
lar has a variation of seven sizes; 12, 15, 25, 30, 50, 60,
and 80 ml. The device has mechanical monodisc valves
(Sorin Biomedica Cardio S.p.A, Saluggia, Italy) or poly-
urethane trileaflet valves, and is coated by heparin.6,18,20)
We have no experience with the Berlin HeartVAD. Merkle
and coworkers16)
reported their experiences with the Ber-
lin Heart VAD. They reported 45 cases with the Berlin
Heart VAD system. According to the report in 45 pediat-
Fig. 1. Outcome after mechanical circulatory support in 29 children.
MCS
LVAD, left ventricular assist device; BVAD, biventricular assist device; ECMO,
extracorporeal membrane oxygenation; L, weaned off and alive; HTX, heart
transplantation; MCS, mechanical circulatory support
5. 311
Mechanical Ventricular Circulatory Support in Children
Ann Thorac Cardiovasc Surg Vol. 11, No. 5 (2005)
ric patients, aged 2 days-17 years, the system was im-
planted for long-term support (mean 1-111 days). The
weaning rate was 11.1% and they succeeded in heart trans-
plantation in 17 cases.16)
Thoratec®
VAD is available worldwide for cardiac fail-
ure in children or in adult patients. The availability is al-
ready shown by many reports.1)
We have reported the
availability for a bridge to heart transplantation. Thoratec®
VAD has been used in more than 100 patients in our hos-
pital with different indications and we have had no major
technical problems. The size of the device console and
the paracorporeal location of the blood pumps make the
system unsuitable in some patients for long time sup-
port.1,21)
HeartMate®
VAD (Thermo Cardiosystems Inc.,
Woburn, Mass, USA) or Novacor®
VAD is implantable
in the body of the patient, the patients are able to have a
good quality of life with a portable battery and control-
ler, and patients are able to go home while awaiting trans-
plantation. Nevertheless, those implantable assist devices
are designed for adult patient and are not suitable for rela-
tively small children.
For the patient awaiting heart transplantation, it is im-
portant, that the device has long durability. A lot of re-
ports have shown that HeartMate®
VAD and Novacor®
VAD have good durability. But those devices are mainly
used for adult patient with a relatively large body surface
area (>1.8 m2
).22)
HeartMate®
VAD or Novacor®
VAD
could be applied for adolescent patients with body surface
area >1.5 m2
in need of long-term circulatory support.
Duncan et al. reported a recovery rate of 60% in pedi-
atric patients with fulminant myocarditis treated with
mechanical support and total survival rate including trans-
plantation was 80%.23)
Survival rate of the postcardiotomy
heart failure was reported from 30% to 70%.11)
Our re-
sults showed that overall survival rate was 44.8%. We
consider our result appropriate, as we had no patients with
acute myocarditis.
Conclusion
Our experience has shown that 1) an extracorporeal cir-
culatory support for example ECMO system is suitable
for small children, 2) a paracorporeal circulatory support
for example Thoratec®
VAD or Medos-HIA system is for
relatively larger children, or necessary biventricular sup-
port and 3) an implantable device, for example Novacor
LVAS, is for large children and patients in need of long
time support as bridging to heart transplantation.
The development of an assist device for children which
has long durability as is desirable. Further clinical and
experimental research and application of those assist de-
vices for children are in progress.
References
1. Farrar DJ, Holman WR, McBride LR, et al. Long-term
follow-up of Thoratec ventricular assist device bridge-
to-recovery patients successfully removed from sup-
port after recovery of ventricular function. J Heart Lung
Transplant 2002; 21: 516–21.
2. Reddy SL, Hasan A, Hamilton LR, et al. Mechanical
versus medical bridge to transplantation in children.
What is the best timing for mechanical bridge? Eur J
Cardiothorac Surg 2004; 25: 605–9.
3. Goldman AP, Cassidy J, de Leval M, et al. The waiting
game: bridging to paediatric heart transplantation. Lan-
cet 2003; 362: 1967–70.
4. Langley SM, Sheppard SV, TsangVT, Monro JL, Lamb
RK. When is extracorporeal life support worthwhile
following repair of congenital heart disease in children?
Eur J Cardiothorac Surg 1998; 13: 520–5.
5. Levi D, Marelli D, Plunkett M, et al. Use of assist de-
vices and ECMO to bridge pediatric patients with car-
diomyopathy to transplantation. J Heart Lung Trans-
plant 2002; 21: 760–70.
6. Hetzer R, Loebe M, Potapov EV, et al. Circulatory sup-
port with pneumatic paracorporeal ventricular assist
device in infants and children. Ann Thorac Surg 1998;
66: 1498–506.
7. del Nido PJ. Extracorporeal membrane oxygenation for
cardiac support in children. Ann Thorac Surg 1996; 61:
336–41.
8. Borowski A, Korb H. Experience with uni- (LVAD)
and biventricular (ECMO) circulatory support in
postcardiotomy pediatric patients. Int J Artif Organs
1997; 20: 695–700.
9. Kirshbom PM, Bridges ND, Myung RJ, Gaynor JW,
Clark BJ, Spray TL. Use of extracorporeal membrane
oxygenation in pediatric thoracic organ transplantation.
J Thorac Cardiovasc Surg 2002; 123: 130–6.
10. Stiller B, Dahnert I, Weng YG, Hennig E, Hezter R,
Lange PE. Children may survive severe myocarditis
with prolonged use of biventricular assist devices. Heart
1999; 82: 237–40.
11. Pennington DG, Swartz MT. Circulatory support in
infants and children. Ann Thorac Surg 1993; 55: 233–
7.
12. Minich LL, Tani LY, Hawkins JA, Orsmond GS, Di
Russo GB, Shaddy RE. Intra-aortic balloon pumping
in children with dilated cardiomyopathy as a bridge to
transplantation. J Heart Lung Transplant 2001; 20:
750–4.
13. Duncan BW, Hraska V, Jonas RA, et al. Mechanical
circulatory support in children with cardiac disease. J
6. 312
Minami et al.
Ann Thorac Cardiovasc Surg Vol. 11, No. 5 (2005)
Thorac Cardiovasc Surg 1999; 117: 529–42.
14. Khan A, Gazzaniga AB. Mechanical circulatory assis-
tance in paediatric patients with cardiac failure.
Cardiovasc Surg 1996; 4: 43–9.
15. Scheinin SA, Radovancevic B, Parnis SM, et al. Me-
chanical circulatory support in children. Eur J
Cardiothorac Surg 1994; 8: 537–40.
16. Merkle F, Boettcher W, Stiller B, Hezter R. Pulsatile
mechanical cardiac assistance in pediatric patients with
the Berlin heart ventricular assist device. J Extra
Corpor Technol 2003; 35: 115–20.
17. Busch U, Waldenberger FR, Redlin M, Hausdorf G,
Konertz W. Successful treatment of postoperative right
ventricular heart failure with the HIA-Medos-assist sys-
tem in a 2-year-old girl. Pediatr Cardiol 1999; 20: 161–
3.
18. Sidiropoulos A, Hotz H, Konertz W. Pediatric circula-
tory support. J Heart Lung Transplant 1998; 17: 1172–
6.
19. Konertz W, Hotz H, Schneider M, Redlin M, Reul H.
Clinical experience with the MEDOS HIA-VAD sys-
tem in infants and children: a preliminary report. Ann
Thorac Surg 1997; 63: 1138–44.
20. Ishino K, Loebe M, Uhlemann F, Weng Y, Hennig E,
Hetzer R. Circulatory support with paracorporeal pneu-
matic ventricular assist device (VAD) in infants and
children. Eur J Cardiothorac Surg 1997; 11: 965–72.
21. Körfer R, El-Banayosy A, Arusoglu L, et al. Single-
center experience with the thoratec ventricular assist
device. J Thorac Cardiovasc Surg 2000; 199: 596–600.
22. Helman DN,Addonizio LJ, Morales DL, et al. Implant-
able left ventricular assist devices can successfully
bridge adolescent patients to transplant. J Heart Lung
Transplant 2000; 19: 121–6.
23. Duncan BW, Bohn DJ, Atz AM, French JW, Laussen
PC, Wessel DL. Mechanical circulatory support for the
treatment of children with acute fulminant myocardi-
tis. J Thorac Cardiovasc Surg 2001; 122: 440–8.